Literature DB >> 15467993

[Serotonergic control of prefrontal cortex].

M V Puig1, P Celada, F Artigas.   

Abstract

INTRODUCTION AND DEVELOPMENT: The prefrontal cortex (PFC) plays a crucial role in higher brain functions such as working memory or cognition and controls, via the excitatory axons of pyramidal neurons, the activity of many subcortical motor and limbic areas. It receives a dense innervation from the brainstem aminergic nuclei, including the serotonergic raphe nuclei. Prefrontal function and metabolism is altered in patients with severe psychiatric disorders, like major depression or schizophrenia. Although the exact role of serotonergic neurotransmission in PFC remains largely unknown, the PFC contains a very large density or serotonin 5-HT1A (inhibitory) and 5-HT2A (excitatory) receptors. In addition, hallucinogens like LSD or DOI are agonists and atypical antipsychotics are antagonists at 5-HT2A receptors. In this review we focus on the main excitatory and inhibitory mechanisms through which serotonin modulates pyramidal and GABAergic neuron activity in the PFC.
CONCLUSIONS: We report on the presence of 5-HT1A and 5-HT2A receptor-mediated responses in pyramidal neurons of the PFC that exert opposite effects on their activity when recorded in vivo in the anesthetized rat. Despite the large co-expression of both receptors in pyramidal neurons of the PFC, physiological amounts of 5-HT mainly inhibit pyramidal neurons. This is probably due to the distinct location of 5-HT1A and 5-HT2A in pyramidal neurons. Thus, 5-HT1A receptors are mainly localized in the axon hillock, where they may have a prominent inhibitory role in the control of pyramidal activity given their coupling to GIRK channels. Moreover, 5-HT can inhibit pyramidal neurons indirectly through the activation of 5-HT2A and 5-HT3 receptors localized in GABAergic interneurons and a subsequent increase in synaptic GABA inputs.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15467993

Source DB:  PubMed          Journal:  Rev Neurol        ISSN: 0210-0010            Impact factor:   0.870


  7 in total

Review 1.  Serotonin and prefrontal cortex function: neurons, networks, and circuits.

Authors:  M Victoria Puig; Allan T Gulledge
Journal:  Mol Neurobiol       Date:  2011-11-11       Impact factor: 5.590

2.  Family-based association analysis of serotonin genes in pathological gambling disorder: evidence of vulnerability risk in the 5HT-2A receptor gene.

Authors:  David Wilson; Daniela Sabbatini da Silva Lobo; Hermano Tavares; Valentim Gentil; Homero Vallada
Journal:  J Mol Neurosci       Date:  2012-06-28       Impact factor: 3.444

Review 3.  Neuroinflammation as a risk factor for attention deficit hyperactivity disorder.

Authors:  Geoffrey A Dunn; Joel T Nigg; Elinor L Sullivan
Journal:  Pharmacol Biochem Behav       Date:  2019-05-16       Impact factor: 3.533

Review 4.  Association of Serotonin Receptors with Attention Deficit Hyperactivity Disorder: A Systematic Review and Meta-analysis.

Authors:  Yu-Wei Hou; Ping Xiong; Xue Gu; Xin Huang; Min Wang; Jing Wu
Journal:  Curr Med Sci       Date:  2018-06-22

5.  Reward circuitry is perturbed in the absence of the serotonin transporter.

Authors:  Elaine L Bearer; Xiaowei Zhang; Davit Janvelyan; Benoit Boulat; Russell E Jacobs
Journal:  Neuroimage       Date:  2009-03-20       Impact factor: 6.556

6.  Serotonin 5-HT2A and 5-HT6 receptors in the prefrontal cortex of Alzheimer and normal aging patients.

Authors:  Dietrich E Lorke; Gang Lu; Eric Cho; David T Yew
Journal:  BMC Neurosci       Date:  2006-04-27       Impact factor: 3.288

7.  Clozapine prevented social interaction deficits and reduced c-Fos immunoreactivity expression in several brain areas of rats exposed to acute restraint stress.

Authors:  Rodolpho Pereira de Oliveira; José Simões de Andrade; Marianna Spina; João Vítor Chamon; Paulo Henrique Dias Silva; Ana Keyla Werder; Daniela Ortolani; Lucas de Santana Cardoso Thomaz; Simone Romariz; Daniel Araki Ribeiro; Beatriz Monteiro Longo; Regina Célia Spadari; Milena de Barros Viana; Liana Melo-Thomas; Isabel Cristina Céspedes; Regina Cláudia Barbosa da Silva
Journal:  PLoS One       Date:  2022-03-03       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.